Arena Pharmaceuticals Inc. and Boehringer Ingelheim Pharma GmbH & Co. KG have jointly patented 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivative G protein-coupled receptor GPR52 agonists.